Biosimilars

Latest News

FDA Approves Second Biosimilars for Prolia/Xgeva
FDA Approves Second Biosimilars for Prolia/Xgeva

February 17th 2025

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA  and Interchangeability | Q&A with Craig Burton, MBA
The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA and Interchangeability | Q&A with Craig Burton, MBA

February 12th 2025

Health of the Biosimilars Industry, Getting Rid of Clinical Trials, PBMs As Obstacles and Other Biosimilar Topics | Q&A With Craig Burton, MBA
Health of the Biosimilars Industry, Getting Rid of Clinical Trials, PBMs As Obstacles and Other Biosimilar Topics | Q&A With Craig Burton, MBA

February 11th 2025

FDA Approves Third Biosimilar of Actemra
FDA Approves Third Biosimilar of Actemra

February 3rd 2025

Wezlana, First Stelara Biosimilar To Hit the Market, Available Only Through Optum's Nuvaila
Wezlana, First Stelara Biosimilar To Hit the Market, Available Only Through Optum's Nuvaila

January 22nd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.